# 18F-FES PET/CT in Breast Cancer: Current Evidence and Clinical Applications

## Introduction

16α-[18F]fluoro-17β-estradiol (18F-FES) is a radiolabeled estrogen analogue approved by the FDA in 2020 for the detection of estrogen receptor (ER)-positive lesions in patients with recurrent or metastatic breast cancer (1). This imaging modality enables whole-body, non-invasive assessment of functional ER expression, offering significant advantages over conventional tissue biopsy (2).

## Diagnostic Performance

### Detection of Metastatic Disease

Multiple recent studies have evaluated the diagnostic accuracy of 18F-FES PET/CT. Shin et al. demonstrated excellent diagnostic performance for detecting recurrent and metastatic disease (3), while Knip et al. compared 18F-FES with 18F-FDG PET for staging grade 1-2 ER-positive tumors (4). Both studies reported sensitivities approaching 100%.

**Edge case: citations groupees adjacentes (espaces)**

Trois citations adjacentes separees par des espaces: (3–5)

Syntaxe: `(3–5)` → groupees en plage

### Comparison with FDG-PET

The comparison between FES-PET and FDG-PET is particularly relevant for low-grade tumors. As noted by several authors (4,6,7), FES-PET may outperform FDG-PET in tumors with low metabolic activity but high ER expression.

**Edge case: citations collees sans espace**

Syntaxe: `(4,6,7)` → groupees avec virgules

## Predicting Response to Endocrine Therapy

### Meta-analyses Evidence

Two comprehensive meta-analyses have examined the role of FES-PET in predicting response to endocrine therapy (8,9). These studies pooled data from multiple centers and confirmed the prognostic value of FES uptake.

**Edge case: syntaxe Pandoc**

Syntaxe: `(8,9)` → groupees avec virgules

### Clinical Decision Making

The impact of FES-PET on clinical decisions was assessed by Ryu et al. (1), who found that imaging results modified treatment plans in a significant proportion of patients.

**Edge case: citation avec locator**

Syntaxe: `(1)` → numero + locator

## Guiding Treatment Selection

Recent work from Fudan University (10) screened over 1600 patients and demonstrated that FES-guided therapy selection improved progression-free survival. This finding was supported by the systematic review from Xu et al. (5).

**Edge case: citations avec URLs (non-adjacentes)**

Syntaxe: `(10) ... texte ... (5)` → NON groupees car separees par texte

## Automated Lesion Detection

With the advent of artificial intelligence, Miller et al. (7) evaluated automated tools for lesion detection on FES-PET images. Their concordance analysis with standard-of-care imaging showed promising results for clinical implementation.

## Comprehensive Reviews

Several umbrella reviews and meta-analyses have synthesized the current evidence (2,5,9). These reviews highlight the growing body of literature supporting FES-PET integration into clinical practice guidelines, including the NCCN recommendations.

**Edge case: groupe de 3 citations adjacentes**

Syntaxe: `(2,5,9)` → groupees

## ER Heterogeneity Assessment

One unique advantage of FES-PET is its ability to assess ER heterogeneity across multiple metastatic sites. This was demonstrated in patients with mixed ER expression patterns (1,6).

**Edge case: citations adjacentes avec URLs**

Syntaxe: `(1,6)` → groupees (URLs ignorees pour le formatage)

## Discussion

The evidence from diagnostic studies (3,4,7), prognostic analyses (8–10), and clinical impact assessments (1) consistently supports the value of 18F-FES PET/CT in managing ER-positive breast cancer.

**Edge case: syntaxe Pandoc avec plusieurs groupes**

- `(3,4,7)` → groupe 1
- `(8–10)` → groupe 2
- `(1)` → citation simple

Compared to traditional biopsy approaches, FES-PET offers several advantages. First, it enables non-invasive whole-body assessment (2). Second, it can detect ER heterogeneity that might be missed by single-site biopsy (6). Third, it has demonstrated clinical impact on treatment decisions (1).

**Edge case: citations non-groupees**

Trois citations separees par du texte → chacune reste individuelle

## Conclusion

18F-FES PET/CT has emerged as a valuable imaging modality for ER-positive breast cancer. The accumulated evidence from multiple studies (1–10) supports its integration into clinical practice for staging, restaging, and treatment selection.

**Edge case: toutes les 10 citations adjacentes**

Toutes les 10 references listees → plage complete (1-10)

## References

<div class="csl-bib-body">
  <div class="csl-entry">
    <div class="csl-left-margin">1. </div><div class="csl-right-inline">Specht JM, van Geel JJ, Song S, et al. The Role of Estrogen Receptor-Targeted PET with 16α-18F-Fluoro-17β-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis. J Nucl Med. 2026;67:36–42.</div>
  </div>
  <div class="csl-entry">
    <div class="csl-left-margin">2. </div><div class="csl-right-inline">Hunter NB, Peterson LM, Specht JM, et al. Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer. Breast Cancer Res. 2025;27:23.</div>
  </div>
  <div class="csl-entry">
    <div class="csl-left-margin">3. </div><div class="csl-right-inline">Xie Y, Chen Y, Liu C, et al. 18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR+/HER2- metastatic breast cancer: impact on progression free survival. Eur J Nucl Med Mol Imaging. 2025;53:374–388.</div>
  </div>
  <div class="csl-entry">
    <div class="csl-left-margin">4. </div><div class="csl-right-inline">Miller R, Battle M, Wangerin K, et al. Evaluating Automated Tools for Lesion Detection on 18F Fluoroestradiol PET/CT Images and Assessment of Concordance with Standard-of-Care Imaging in Metastatic Breast Cancer. Radiology: Imaging Cancer. 2025;7:e240253.</div>
  </div>
  <div class="csl-entry">
    <div class="csl-left-margin">5. </div><div class="csl-right-inline">Cuzzocrea M, Di Micco R, Colombo GE, et al. The Role of [18F]FES PET/CT in Breast Cancer Management: An Umbrella Review. Cancers. 2025;17:1644.</div>
  </div>
  <div class="csl-entry">
    <div class="csl-left-margin">6. </div><div class="csl-right-inline">Shin E, Han S, Ryu J, et al. Diagnostic Accuracy of 18F-FES PET/CT for the Detection of Recurrent and Metastatic Breast Cancer. Clin Nucl Med. 2025;50:31–37.</div>
  </div>
  <div class="csl-entry">
    <div class="csl-left-margin">7. </div><div class="csl-right-inline">Knip JJ, Iqbal R, Bonjer EC, et al. The Diagnostic Accuracy of 18F-FDG PET and 18F-FES PET for Staging Grade 1-2 Estrogen Receptor-Positive Breast Cancer. Radiology. 2025;314:e241850.</div>
  </div>
  <div class="csl-entry">
    <div class="csl-left-margin">8. </div><div class="csl-right-inline">Xu Y, Yao R, Hao Z, et al. [18F]F-FES PET for diagnosis, staging, and endocrine therapy prediction in ER-positive breast cancer: a systematic review and meta-analysis. EJNMMI Res. 2025;15:17.</div>
  </div>
  <div class="csl-entry">
    <div class="csl-left-margin">9. </div><div class="csl-right-inline">Ryu J, Hyung J, Han S, et al. Impact of 18F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer. J Nucl Med. 2024;65:1689–1694.</div>
  </div>
  <div class="csl-entry">
    <div class="csl-left-margin">10. </div><div class="csl-right-inline">Parihar AS, Vaz S, Sutcliffe S, et al. 18F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Metaanalysis. J Nucl Med. 2025;66:692–699.</div>
  </div>
</div>